Mechanistic Roles of Long mcRNA-regulated Gene Transcription in Prostate Cancer
Mechanistic Roles of Long mcRNA-regulated Gene Transcription in Prostate Cancer
批准号:
8653043
负责人:
Liuqing Yang
金额:
$23.41万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-06-15 至 2016-05-31
关键词:
American Cancer SocietyAndrogen ReceptorAndrogensAnimal ModelAntibodiesBiological AssayCell NucleusCessation of lifeChIP-seqChromatinComplexCoupledCytoplasmic GranulesDataDevelopmentDiagnosisEnvironmentEventExcisionFlow CytometryFluorescent in Situ HybridizationFunctional RNAGene ActivationGene ExpressionGene Expression ProfileGene Expression RegulationGene TargetingGenesGenetic TranscriptionGrowthHistonesHomeostasisHumanKDM5B geneKnowledgeLigandsLinkLocationMaintenanceMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMass Spectrum AnalysisMediatingMethodsMethylationModificationMolecularNeoplasm MetastasisNuclearNuclear ReceptorsNucleic Acid Regulatory SequencesPhenotypePlayPolycombPositioning AttributeProcessProstateProstatic NeoplasmsProteinsRNAReaderRegulationRegulator GenesRoleSiteSmall Interfering RNAStagingStructureTestingTherapeuticTranscriptional RegulationUnited StatesUntranslated RNAanticancer researchbasecancer initiationdemethylationgene repressiongenome-widein vivoinnovationinterestknock-downmalemanmenmouse modelnovelpre-clinicalprogramspromoterprostate cancer cellreproductive functiontranscription factortumor growthtumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Prostate cancer is the most common non-skin malignancy in men and is responsible for more deaths
than any other cancer, except for lung cancer. According to the American Cancer Society (ACS), about
218,890 new cases of prostate cancer were diagnosed in the United States during 2007 and about 1 man in 6
will be diagnosed with prostate cancer during his lifetime. It is well established that androgen plays an
important role in promoting prostate cancer initiation/development. Therefore, it is essential to understand the
mechanism of androgen receptor (AR) target gene expression, which is at the center stage of prostate cancer
research. Although our knowledge of the molecular mechanisms by which the AR regulates gene transcription
and its possible link to prostate cancer is increasing, several interesting questions remain to be answered.
Thus, the major hypothesis in this proposal is that ncRNA-dependent relocation of gene regulatory regions
based on covalent modifications of specific histone mark "readers," such as Pc2, are critical components of the
regulatory machinery underlying the transcriptional actions of nuclear receptors, including AR. Specifically, the
proposed study aims to: 1) define non-histone methylation/demethylation of Pc2 as a novel molecular strategy
responsible for genome-wide AR transcriptional programs; 2) determine the androgen-induced relocation of AR
target genes between PcG bodies and interchromatin granules and the potential involvement of ncRNAs; 3)
investigate the role of ncRNAs in modulating androgen-dependent gene regulatory programs and their
potential relevance for the prostate cancer development. The major novel aspect of this study is that it
uncovers a new component of the regulatory machinery required for androgen-dependent gene regulatory
programs by providing a biologically and clinically innovative mechanism by which AR-targeted genes are
regulated, in part, by the dynamic ligand-dependent relocation from transcriptional repressive to permissive
nuclear bodies involving the functional interplay between the non-histone Pc2 methylation events and the
resultant specific ncRNA associations. Generally, this mechanism may serve to integrate actions of
transcription factor/co-regulators, non-histone protein methylation, and ncRNAs resident in distinct subnuclear
architectural structures to achieve coordinated activation for nuclear receptor target genes. The results from
the proposed study may facilitate the development of novel prostate diagnosis and therapeutic strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rational Combination Therapy with PARP Inhibitors in Triple Negative Breast Cancer
-
批准号:10015209
-
项目类别:
-
资助金额:$42.54万
-
财政年份:2017
-
负责人:Liuqing Yang
-
依托单位:
Rational Combination Therapy with PARP Inhibitors in Triple Negative Breast Cancer
-
批准号:10229578
-
项目类别:
-
资助金额:$42.54万
-
财政年份:2017
-
负责人:Liuqing Yang
-
依托单位:
Rational Combination Therapy with PARP Inhibitors in Triple Negative Breast Cancer
-
批准号:9764288
-
项目类别:
-
资助金额:$41.26万
-
财政年份:2017
-
负责人:Liuqing Yang
-
依托单位:
Combinatorial Treatment Strategies to Counteract EGFR Resistance
-
批准号:10247729
-
项目类别:
-
资助金额:$36.4万
-
财政年份:2017
-
负责人:Liuqing Yang
-
依托单位:
Combinatorial Treatment Strategies to Counteract EGFR Resistance
-
批准号:9362260
-
项目类别:
-
资助金额:$38.85万
-
财政年份:2017
-
负责人:Liuqing Yang
-
依托单位:
Combinatorial Treatment Strategies to Counteract EGFR Resistance
-
批准号:9751236
-
项目类别:
-
资助金额:$35.31万
-
财政年份:2017
-
负责人:Liuqing Yang
-
依托单位:
Mechanistic Roles of Long mcRNA-regulated Gene Transcription in Prostate Cancer
-
批准号:8682888
-
项目类别:
-
资助金额:$22.6万
-
财政年份:2013
-
负责人:Liuqing Yang
-
依托单位:
Mechanistic Roles of Long mcRNA-regulated Gene Transcription in Prostate Cancer
-
批准号:8862424
-
项目类别:
-
资助金额:$22.39万
-
财政年份:2013
-
负责人:Liuqing Yang
-
依托单位:
Role of ncRNA-mediated Relocation of AR Transcription Units in Prostate Cancer
-
批准号:8281227
-
项目类别:
-
资助金额:$14.03万
-
财政年份:2012
-
负责人:Liuqing Yang
-
依托单位:
海外基金